Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
Vanja Đurić, Mounira Banasr, Tina Franklin, et al.
The International Journal of Neuropsychopharmacology (2017) Vol. 20, Iss. 10, pp. 788-796
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

<p>Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment</p>
Christoph U. Correll, Nina R. Schooler
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 519-534
Open Access | Times Cited: 553
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
Stephen M. Stahl, Sarah Laredo, Debbi Ann Morrissette
Therapeutic Advances in Psychopharmacology (2020) Vol. 10, pp. 204512532090575-204512532090575
Open Access | Times Cited: 216
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Wolfgang Fleischhacker, Silvana Galderisi, I. Laszlovszky, et al.
European Psychiatry (2019) Vol. 58, pp. 1-9
Open Access | Times Cited: 103
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
I. Laszlovszky, Ágota Barabássy, György Németh
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3652-3673
Open Access | Times Cited: 59
Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Gary S. Sachs, Paul Yeung, Ludmyla Rekeda, et al.
American Journal of Psychiatry (2023) Vol. 180, Iss. 3, pp. 241-251
Closed Access | Times Cited: 31
Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?
Pengfei Yang, Joel S. Perlmutter, Tammie L.S. Benzinger, et al.
Ageing Research Reviews (2019) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 73
Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
Béla Kiss, I. Laszlovszky, Balázs Krámos, et al.
Biomolecules (2021) Vol. 11, Iss. 1, pp. 104-104
Open Access | Times Cited: 51
Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?
Fangyi Zhao, Ziqian Cheng, Jingjing Piao, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 32
Cariprazine Augmentation in Treatment-Resistant Bipolar Depression: Data from a Retrospective Observational Study
Elena Teobaldi, Enrico Pessina, Azzurra Martini, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 10, pp. 1742-1748
Open Access | Times Cited: 7
Cariprazine in the treatment of schizophrenia
Suresh Durgam, Robert E. Litman, Kelly Papadakis, et al.
International Clinical Psychopharmacology (2015) Vol. 31, Iss. 2, pp. 61-68
Open Access | Times Cited: 62
Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Willie Earley, Hua Guo, David G. Daniel, et al.
Schizophrenia Research (2018) Vol. 204, pp. 282-288
Open Access | Times Cited: 58
International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets
Filippo Caraci, Francesca Calabrese, Raffaella Molteni, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 475-504
Open Access | Times Cited: 57
The role of dopamine D3receptors in the mechanism of action of cariprazine
Francesca Calabrese, Frank I. Tarazi, Giorgio Racagni, et al.
CNS Spectrums (2019) Vol. 25, Iss. 3, pp. 343-351
Open Access | Times Cited: 52
Efficacy of adjunctive low-dose cariprazine in major depressive disorder
Maurizio Fava, Suresh Durgam, Willie Earley, et al.
International Clinical Psychopharmacology (2018) Vol. 33, Iss. 6, pp. 312-321
Open Access | Times Cited: 51
Residual avoidance: A new, consistent and repeatable readout of chronic stress-induced conflict anxiety reversible by antidepressant treatment
Thomas D. Prévot, Keith A. Misquitta, Corey Fee, et al.
Neuropharmacology (2019) Vol. 153, pp. 98-110
Open Access | Times Cited: 45
Novel Molecular Targets of Antidepressants
Małgorzata Jarończyk, Jarosław Walory
Molecules (2022) Vol. 27, Iss. 2, pp. 533-533
Open Access | Times Cited: 24
SRIs Augmentation with Cariprazine In Patients with Treatment Resistant Obsessive-Compulsive Disorder: A Retrospective Observational Study
Vassilis Martiadis, Enrico Pessina, Azzurra Martini, et al.
CNS Spectrums (2024), pp. 1-4
Open Access | Times Cited: 5
Effects of brexpiprazole on patient life engagement in schizophrenia: post hoc analysis of Positive and Negative Syndrome Scale data
Zahinoor Ismail, Stine R. Meehan, Anja Farovik, et al.
Current Medical Research and Opinion (2025), pp. 1-9
Open Access
A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
Silvio Caccia, Roberto William Invernizzi, Alessandro Nobili, et al.
Therapeutics and Clinical Risk Management (2013), pp. 319-319
Open Access | Times Cited: 52
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Stephen R. Marder, W. Wolfgang Fleischhacker, Willie Earley, et al.
European Neuropsychopharmacology (2018) Vol. 29, Iss. 1, pp. 127-136
Open Access | Times Cited: 45
Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Leslie Citrome
Neuropsychiatric Disease and Treatment (2018) Vol. Volume 14, pp. 2563-2577
Open Access | Times Cited: 42
<p>Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine</p>
Béla Kiss, Zsolt Némethy, Károly Fazekas, et al.
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3229-3248
Open Access | Times Cited: 41
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
Nakao Iwata, Jun Ishigooka, Won‐Hyoung Kim, et al.
Schizophrenia Research (2019) Vol. 215, pp. 408-415
Open Access | Times Cited: 37
Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms
Koen Demyttenaere, Nicolas Leenaerts, K. Acsai, et al.
European Psychiatry (2021) Vol. 65, Iss. 1
Open Access | Times Cited: 27
The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis
Bing Bai, Yuwei Li, Xi Chen, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top